RS
ACRS icon

R Squared’s Aclaris Therapeutics ACRS Stock Holding History

R Squared’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,408
Closed -$37.3K – 479
2025
Q4 		$37.3K Buy
+12,408
New +$31.4K 0.02% 473
2025
Q1 		– Sell
-610
Closed -$1.51K – 305
2024
Q4 		$1.51K Buy
+610
New +$1.52K ﹤0.01% 1490

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

R Squared's ACRS Position: Q1 2026 in Review

R Squared sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 12,408 shares — an estimated $37.3K sold.

R Squared first reported a position in ACRS in Q4 2024 and held it in 2 quarters. The position peaked at $37.3K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • R Squared reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 12,408 Aclaris Therapeutics shares in Q1 2026, an estimated $37.3K.
  • R Squared first reported a position in Aclaris Therapeutics in Q4 2024 and held it in 2 quarters.
  • R Squared's Aclaris Therapeutics position peaked at $37.3K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.